These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 29642146

  • 1. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
    Lv X, Zhang Y, Niu Y, Song Q, Zhao Q.
    Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
    [Abstract] [Full Text] [Related]

  • 2. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J.
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [Abstract] [Full Text] [Related]

  • 3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S.
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [Abstract] [Full Text] [Related]

  • 4. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.
    Hao G, Wang Z, Guo R, Chen Z, Wang X, Zhang L, Li W.
    BMC Cardiovasc Disord; 2014 Oct 25; 14():148. PubMed ID: 25344747
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
    Ohtsubo T, Shibata R, Kai H, Okamoto R, Kumagai E, Kawano H, Fujiwara A, Kitazono T, Murohara T, Arima H.
    Hypertens Res; 2019 May 25; 42(5):641-649. PubMed ID: 30948834
    [Abstract] [Full Text] [Related]

  • 6. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.
    Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V, Alam M, Addison D, Macedo F, Virani S, Birnbaum Y.
    Cardiovasc Drugs Ther; 2016 Apr 11; 30(2):189-98. PubMed ID: 26861251
    [Abstract] [Full Text] [Related]

  • 8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, Li J, Zhang J, Xu Y, Lu H, Xu D.
    BMC Cardiovasc Disord; 2017 Oct 05; 17(1):257. PubMed ID: 28982370
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH.
    Mayo Clin Proc; 2016 Jan 05; 91(1):51-60. PubMed ID: 26763511
    [Abstract] [Full Text] [Related]

  • 10. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R.
    Int J Cardiol; 2016 Aug 15; 217():128-34. PubMed ID: 27179902
    [Abstract] [Full Text] [Related]

  • 11. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q, Li Q.
    Kidney Blood Press Res; 2018 Aug 15; 43(3):768-779. PubMed ID: 29794446
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ, Chu H, Ou SM, Chen YT.
    Int J Cardiol; 2015 Nov 15; 199():283-9. PubMed ID: 26218587
    [Abstract] [Full Text] [Related]

  • 13. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X, Ma L, Li Z.
    J Endocrinol Invest; 2020 Jul 15; 43(7):959-972. PubMed ID: 31939197
    [Abstract] [Full Text] [Related]

  • 14. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
    Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P.
    J Am Coll Cardiol; 2013 Jan 15; 61(2):131-42. PubMed ID: 23219304
    [Abstract] [Full Text] [Related]

  • 15. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
    Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, Shi XY.
    Cochrane Database Syst Rev; 2016 Jan 27; 2016(1):CD009210. PubMed ID: 26816003
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
    Batty JA, Tang M, Hall M, Ferrari R, Strauss MH, Hall AS.
    Syst Rev; 2018 Aug 25; 7(1):131. PubMed ID: 30144828
    [Abstract] [Full Text] [Related]

  • 17. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH, Hall AS.
    Prog Cardiovasc Dis; 2016 Aug 25; 58(5):473-82. PubMed ID: 26586276
    [Abstract] [Full Text] [Related]

  • 18. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q, Tang S, Li Y.
    Ann Palliat Med; 2022 Apr 25; 11(4):1253-1263. PubMed ID: 34775774
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
    Al Khalaf MM, Thalib L, Doi SA.
    Am J Cardiovasc Drugs; 2009 Apr 25; 9(1):29-43. PubMed ID: 19178130
    [Abstract] [Full Text] [Related]

  • 20. Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
    Avgerinos I, Karagiannis T, Matthews DR, Tsapas A, Bekiari E.
    Diabetes Obes Metab; 2023 Oct 25; 25(10):3020-3029. PubMed ID: 37435776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.